Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma, Inc.'s focus is to deliver DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference.
都柏林，2024年11月20日 /PRNewswire/ -- theravance biopharma, Inc.（纳斯达克：TBPH）将于12月3日（星期二）东部标准时间上午11:15（太平洋标准时间上午8:15/格林尼治标准时间下午4:15）参加第七届evercore健康会议的炉边聊天，并将在会议上与投资社区举行面对面的会议。
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.
活动的网络直播可以通过访问Theravance.com，在投资者部分的活动和演示中进行访问。网络直播的重播将在公司的网站上存档30天。
About Theravance Biopharma
关于theravance biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
theravance biopharma, Inc.的专注是提供改善人们生活的药物。为了实现这一目标，theravance biopharma利用数十年的专业知识，开发了FDA批准的YUPELRI（revefenacin）吸入溶液，用于维持治疗慢性阻塞性肺疾病（COPD）患者。Ampreloxetine是其晚期研究中的每日一次去甲肾上腺素再摄取抑制剂，针对多系统萎缩（MSA）患者的症状性神经性直立性低血压（nOH）进行开发，有望成为一类治疗，针对MSA患者的一组主要症状。公司致力于创造/推动股东价值。
For more information, please visit .
更多资讯，请访问。
THERAVANCE BIOPHARMA, THERAVANCE and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
theravance biopharma, theravance 和交叉/科创板标志是theravance biopharma集团公司的注册商标（在美国和一些其他国家）。
YUPELRI is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
YUPELRI是Viatris公司的Mylan Specialty L.P.的注册商标。在此新闻稿中出现的其他公司的商标、商号或服务标志均为其各自所有者的财产。
Contact:
[email protected]
650-808-4045
联系方式：
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
来源：theravance biopharma, Inc.
